
Sagar V Parikh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11909232/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 2018, 20, 97-170.	1.9	1,079
2	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 540-560.	1.9	746
3	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders, 2013, 15, 1-44.	1.9	740
4	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders, 2009, 11, 225-255.	1.9	545
5	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 561-575.	1.9	415
6	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults Journal of Affective Disorders, 2009, 117, S26-S43.	4.1	357
7	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 524-539.	1.9	340
8	Suicide risk in bipolar patients: the role of coâ€morbid substance use disorders. Bipolar Disorders, 2003, 5, 58-61.	1.9	235
9	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 576-587.	1.9	227
10	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 510-523.	1.9	209
11	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disorders, 2006, 8, 721-739.	1.9	202
12	Early age at onset as a risk factor for poor outcome of bipolar disorder. Journal of Psychiatric Research, 2003, 37, 297-303.	3.1	198
13	Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research, 2019, 111, 59-67.	3.1	197
14	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. Journal of Affective Disorders, 2009, 117, S1-S2.	4.1	192
15	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults Journal of Affective Disorders, 2009, 117, S44-S53.	4.1	175
16	Major Depression in Individuals With a History of Childhood Physical or Sexual Abuse: Relationship to Neurovegetative Features, Mania, and Gender. American Journal of Psychiatry, 1998, 155, 1746-1752.	7.2	166
17	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 588-603.	1.9	165
18	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. Journal of Affective Disorders, 2009, 117, S15-S25.	4.1	154

#	Article	IF	CITATIONS
19	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. Nature Communications, 2017, 8, 15497.	12.8	144
20	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. I. Classification, Burden and Principles of Management. Journal of Affective Disorders, 2009, 117, S5-S14.	4.1	128
21	ls Cognitive-Behavioural Therapy More Effective Than Psychoeducation in Bipolar Disorder?. Canadian Journal of Psychiatry, 2008, 53, 441-448.	1.9	121
22	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry, 2016, 16, 105.	2.6	114
23	A Randomized Controlled Trial of Psychoeducation or Cognitive-Behavioral Therapy in Bipolar Disorder. Journal of Clinical Psychiatry, 2012, 73, 803-810.	2.2	111
24	Genome-wide association study of bipolar disorder in Canadian and UK populations corroborates disease loci including SYNE1 and CSMD1. BMC Medical Genetics, 2014, 15, 2.	2.1	106
25	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults Journal of Affective Disorders, 2009, 117, S54-S64.	4.1	91
26	Stigma and bipolar disorder: A review of the literature. Journal of Affective Disorders, 2013, 150, 181-191.	4.1	91
27	An Unstable Trinucleotide-Repeat Region on Chromosome 13 Implicated in Spinocerebellar Ataxia: A Common Expansion Locus. American Journal of Human Genetics, 2000, 66, 819-829.	6.2	85
28	Genetic Association Analysis of Serotonin System Genes in Bipolar Affective Disorder. American Journal of Psychiatry, 1999, 156, 136-138.	7.2	81
29	Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 36-43.	1.7	81
30	Sociodemographic, clinical, and attitudinal characteristics of the untreated depressed in Ontario. Journal of Affective Disorders, 1999, 53, 153-162.	4.1	78
31	Chronic Lithium Treatment Attenuates Intracellular Calcium Mobilization. Neuropsychopharmacology, 2004, 29, 759-769.	5.4	76
32	Copy number variant study of bipolar disorder in Canadian and UK populations implicates synaptic genes. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 303-313.	1.7	76
33	Altered TRPC7 gene expression in bipolar-I disorder. Biological Psychiatry, 2001, 50, 620-626.	1.3	68
34	The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction. Current Pharmaceutical Design, 2012, 18, 5976-5989.	1.9	61
35	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	2.2	61
36	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. Journal of Affective Disorders, 2018, 227, 542-549.	4.1	59

#	Article	IF	CITATIONS
37	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 506-509.	1.9	58
38	Mental Health Treatment in Ontario: Selected Comparisons between the Primary Care and Specialty Sectors. Canadian Journal of Psychiatry, 1997, 42, 929-934.	1.9	57
39	The Canadian Network for Wood and Anxiety Treatments (CANWAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Con L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.	cernant	54
40	i>TRPM2 variants and bipolar disorder risk: confirmation in a familyâ€based association study. Bipolar Disorders, 2009, 11, 1-10.	1.9	52
41	Using theatre to address mental illness stigma: a knowledge translation study in bipolar disorder. International Journal of Bipolar Disorders, 2014, 2, 1.	2.2	52
42	A pilot randomized controlled trial of telephone-based cognitive behavioural therapy for preoperative bariatric surgery patients. Behaviour Research and Therapy, 2016, 80, 17-22.	3.1	51
43	Coping styles in prodromes of bipolar mania. Bipolar Disorders, 2007, 9, 589-595.	1.9	50
44	Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression. JAMA Network Open, 2020, 3, e1918377.	5.9	49
45	Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder. British Journal of Psychiatry, 2013, 203, 358-365.	2.8	47
46	E-health. Current Opinion in Psychiatry, 2015, 28, 13-17.	6.3	46
47	Cognitive Behavioral Therapy for Bariatric Surgery Patients: Preliminary Evidence for Feasibility, Acceptability, and Effectiveness. Cognitive and Behavioral Practice, 2013, 20, 529-543.	1.5	42
48	Applying Prochaska's model of change to needs assessment, programme planning and outcome measurement. Journal of Evaluation in Clinical Practice, 2001, 7, 365-371.	1.8	41
49	A Pilot Study on Telephone Cognitive Behavioral Therapy for Patients Six-Months Post-Bariatric Surgery. Obesity Surgery, 2017, 27, 670-675.	2.1	39
50	Depression in Ontario: under-treatment and factors related to antidepressant use. Journal of Affective Disorders, 1999, 52, 67-76.	4.1	38
51	Associated disturbances in calcium homeostasis and G protein–mediated cAMP signaling in bipolar I disorder. Biological Psychiatry, 2000, 48, 665-673.	1.3	38
52	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis. Psychological Medicine, 2021, 51, 2742-2751.	4.5	38
53	Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. Neuropsychopharmacology, 2020, 45, 283-291.	5.4	37
54	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. Journal of Psychiatry and Neuroscience, 2019, 44, 223-236.	2.4	37

#	Article	IF	CITATIONS
55	Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Annals of Clinical Psychiatry, 2015, 27, 142-9.	0.6	37
56	Advancing Bipolar Disorder: Key Lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Canadian Journal of Psychiatry, 2010, 55, 136-143.	1.9	34
57	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. Translational Psychiatry, 2019, 9, 254.	4.8	33
58	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disorders, 2021, 23, 767-788.	1.9	32
59	Patient Attitudes regarding Causes of Depression: Implications for Psychoeducation. Canadian Journal of Psychiatry, 2003, 48, 493-495.	1.9	31
60	Reducing stigma toward people with bipolar disorder: Impact of a filmed theatrical intervention based on a personal narrative. International Journal of Social Psychiatry, 2014, 60, 741-750.	3.1	31
61	Further support for association of the mitochondrial complex I subunit gene NDUFV2 with bipolar disorder. Bipolar Disorders, 2008, 10, 105-110.	1.9	30
62	Applying a â€~stages of change' model to enhance a traditional evaluation of a research transfer course. Journal of Evaluation in Clinical Practice, 2003, 9, 385-390.	1.8	29
63	Linking medical faculty stress/burnout to willingness to implement medical school curriculum change: a preliminary investigation. Journal of Evaluation in Clinical Practice, 2016, 22, 86-92.	1.8	29
64	Do symptoms of bipolar disorder exhibit seasonal variation? A multisite prospective investigation. Bipolar Disorders, 2011, 13, 687-695.	1.9	27
65	Implementing Measurement-Based Care for Depression: Practical Solutions for Psychiatrists and Primary Care Physicians. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 79-90.	2.2	27
66	Using a simulation centre to evaluate preliminary acceptability and impact of an artificial intelligence-powered clinical decision support system for depression treatment on the physician–patient interaction. BJPsych Open, 2021, 7, e22.	0.7	26
67	The Michigan Peer-to-Peer Depression Awareness Program: School-Based Prevention to Address Depression Among Teens. Psychiatric Services, 2018, 69, 487-491.	2.0	25
68	A tailored educational intervention improves doctor's performance in managing depression: a randomized controlled trial. Journal of Evaluation in Clinical Practice, 2013, 19, 16-24.	1.8	23
69	Schema therapy for bipolar disorder: A conceptual model and future directions. Journal of Affective Disorders, 2013, 148, 118-122.	4.1	23
70	Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. Neuropsychopharmacology, 2020, 45, 1390-1397.	5.4	23
71	The 5HT1Dβ Receptor Gene in Bipolar Disorder A Family-based Association Study. Neuropsychopharmacology, 2001, 25, 608-613.	5.4	22
72	Improving care and wellness in bipolar disorder: origins, evolution and future directions of a collaborative knowledge exchange network. International Journal of Mental Health Systems, 2012, 6, 16.	2.7	22

#	Article	IF	CITATIONS
73	Comorbid Anxiety Disorders in Canadians with Bipolar Disorder: Clinical Characteristics and Service Use. Canadian Journal of Psychiatry, 2013, 58, 393-401.	1.9	22
74	Effects on Knowledge and Attitudes of Using Stages of Change to Train General Practitioners on Management of Depression: A Randomized Controlled Study. Canadian Journal of Psychiatry, 2009, 54, 693-700.	1.9	19
75	Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder. Bipolar Disorders, 2015, 17, 86-96.	1.9	19
76	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1173-1182.	2.3	18
77	Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial. BMC Psychiatry, 2019, 19, 420.	2.6	18
78	Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. Psychiatry Research, 2020, 290, 113017.	3.3	18
79	Clinical and demographic factors associated with delayed diagnosis of bipolar disorder: Data from Health Outcomes and Patient Evaluations in Bipolar Disorder (HOPE-BD) study. Journal of Affective Disorders, 2022, 296, 506-513.	4.1	16
80	Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. Journal of Clinical Psychiatry, 2019, 80, .	2.2	16
81	Bipolar disorder with comorbid anxiety disorders: impact of comorbidity on treatment outcome in cognitive-behavioral therapy and psychoeducation. International Journal of Bipolar Disorders, 2013, 1, 15.	2.2	15
82	Remission and recurrence in bipolar disorder: The data from health outcomes and patient evaluations in bipolar disorder (HOPE-BD) study. Journal of Affective Disorders, 2020, 268, 150-157.	4.1	15
83	Evaluating the Clinical Feasibility of an Artificial Intelligence–Powered, Web-Based Clinical Decision Support System for the Treatment of Depression in Adults: Longitudinal Feasibility Study. JMIR Formative Research, 2021, 5, e31862.	1.4	15
84	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. Bipolar Disorders, 2013, 15, 58-60.	1.9	14
85	Telephone-based cognitive behavioural therapy for female patients 1-year post-bariatric surgery: A pilot study. Obesity Research and Clinical Practice, 2019, 13, 499-504.	1.8	14
86	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. American Journal of Geriatric Psychiatry, 2020, 28, 933-945.	1.2	13
87	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments. Focus (American Psychiatric Publishing), 2018, 16, 85-94.	0.8	12
88	Collaborating with individuals with lived experience to adapt CANMAT clinical depression guidelines into a patient treatment guide: The CHOICEâ€D coâ€design process. Journal of Evaluation in Clinical Practice, 2020, 26, 1259-1269.	1.8	12
89	Improving continuing medical education by enhancing interactivity: lessons from Iran. Journal of Advances in Medical Education and Professionalism, 2016, 4, 54-63.	0.2	12
90	Antidepressants are not all created equal. Lancet, The, 2009, 373, 700-701.	13.7	11

#	Article	IF	CITATIONS
91	Psychosocial Interventions for Bipolar Disorder and Coping Style Modification: Similar Clinical Outcomes, Similar Mechanisms?. Canadian Journal of Psychiatry, 2013, 58, 482-486.	1.9	11
92	Effects of somatic treatments on suicidal ideation and completed suicides. Brain and Behavior, 2021, 11, e2381.	2.2	11
93	Adapting the Goal Attainment Approach for Major Depressive Disorder. Neurology and Therapy, 2019, 8, 167-176.	3.2	10
94	Design and Feasibility of a New Cognitive-Behavioural Therapy Course Using a Longitudinal Interactive Format. Canadian Journal of Psychiatry, 2004, 49, 696-700.	1.9	9
95	Association analysis of <i>DAOA</i> and <i>DAO</i> in bipolar disorder: results from two independent caseâ€control studies. Bipolar Disorders, 2010, 12, 579-581.	1.9	9
96	Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 81, .	2.2	9
97	Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. Psychiatry Research, 2021, 296, 113649.	3.3	8
98	Electroconvulsive Therapy in Canada During the First Wave of COVID-19. Journal of ECT, 2021, Publish Ahead of Print, .	0.6	8
99	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. Psychoneuroendocrinology, 2021, 132, 105348.	2.7	8
100	Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study. BMC Psychiatry, 2021, 21, 622.	2.6	8
101	The Effects of Ketamine on Cognition in Unipolar and Bipolar Depression. Journal of Clinical Psychiatry, 2022, 83, .	2.2	7
102	Screening and Treating Mental Disorders in Addiction Treatment Settings: A Stepped Care Model. International Journal of Mental Health and Addiction, 2008, 6, 137-140.	7.4	6
103	More data, more answers: picking the optimal antidepressant. Lancet, The, 2018, 391, 1333-1334.	13.7	6
104	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. Innovations in Clinical Neuroscience, 2020, 17, 30-40.	0.1	6
105	An evaluation of large group cognitive behaviour therapy with mindfulness (CBTm) classes. BMC Psychiatry, 2019, 19, 132.	2.6	5
106	Impact of a Student Pharmacist Driven Medication Reconciliation and Antidepressant Treatment History Project at a Depression Clinic: A Pilot Study. Psychopharmacology Bulletin, 2017, 47, 36-41.	0.0	5
107	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Canadian Journal of Psychiatry, 2023, 68, 299-311.	1.9	5
108	Clinical characteristics of bipolar disorder subjects with large CAG/CTG repeat DNA. Journal of Affective Disorders, 1999, 55, 221-224.	4.1	4

#	Article	IF	CITATIONS
109	Childhood Trauma and Depression. American Journal of Psychiatry, 2003, 160, 1188-1188.	7.2	4
110	Brief Versus Intensive Psychosocial Treatments for Bipolar Disorder: Time for Stepped Care?. American Journal of Psychiatry, 2014, 171, 1335-1335.	7.2	4
111	Videoconferencing Technology to Facilitate a Pilot Training Course in Advanced Psychopharmacology for Psychiatrists. Academic Psychiatry, 2019, 43, 411-416.	0.9	4
112	Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers. Journal of Affective Disorders, 2020, 263, 353-366.	4.1	4
113	Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine. Focus (American Psychiatric Publishing), 2020, 18, 181-192.	0.8	4
114	Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. CNS Drugs, 2021, 35, 439-450.	5.9	4
115	Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder. Psychiatry Research, 2022, 308, 114354.	3.3	4
116	Improving Access to Psychosocial Treatments—Integrating Patient, Provider, and Systems Approaches. Canadian Journal of Psychiatry, 2015, 60, 242-244.	1.9	3
117	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. Translational Psychiatry, 2021, 11, 439.	4.8	3
118	Feasibility of large group cognitive behavioural therapy education classes for anxiety disorders. European Journal for Person Centered Healthcare, 2018, 6, 274.	0.3	3
119	The Impact of Completing Medication Reconciliation and Depression Treatment History in an Outpatient Depression Clinic. Psychopharmacology Bulletin, 2019, 49, 44-55.	0.0	3
120	Going Virtual During a Pandemic: An Academic Psychiatry Department's Experience with Telepsychiatry. Psychopharmacology Bulletin, 2021, 51, 59-68.	0.0	3
121	Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study report. Journal of Affective Disorders, 2022, 300, 50-58.	4.1	3
122	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. Frontiers in Psychiatry, 2022, 13, 816465.	2.6	3
123	Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy. Brain and Behavior, 2022, 12, e2555.	2.2	3
124	Evaluation of a diseaseâ€management intervention designed to reduce depression disability. Journal of Evaluation in Clinical Practice, 2011, 17, 322-325.	1.8	2
125	Bipolar disorder research 2.0: Web technologies for research capacity and knowledge translation. Journal of Evaluation in Clinical Practice, 2017, 23, 1144-1152.	1.8	2
126	Assessment and Treatment of Mood and Anxiety Disorders in the Workplace. Integrating Psychiatry and Primary Care, 2019, , 111-129.	0.3	2

#	Article	IF	CITATIONS
127	"lf you're offered help, take it†A qualitative study examining bariatric patients' experience of telephoneâ€based cognitive behavioural therapy. Clinical Obesity, 2021, 11, e12431.	2.0	2
128	Teaching psychiatric pharmacogenomics effectively: Evaluation of a novel interprofessional online course. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 176-183.	1.0	2
129	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines. Bipolar Disorders, 2013, 15, 338-339.	1.9	1
130	Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies. Journal of Psychiatric Research, 2019, 114, 211-213.	3.1	1
131	Improving psychiatric medication use through the Michigan eâ€psychopharmacology course for nurse practitioners: A preâ€post/followâ€up study. Perspectives in Psychiatric Care, 2020, 56, 547-553.	1.9	1
132	Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report. Pharmacopsychiatry, 2021, 54, 225-231.	3.3	1
133	Expanding the target audience for management guidelines: Coâ€development of the patient and family guide to the CANMAT and ISBD bipolar disorder guidelines. Bipolar Disorders, 2021, 23, 528-530.	1.9	1
134	Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report. Journal of Psychopharmacology, 2022, 36, 604-613.	4.0	1
135	Psychosocial interventions in bipolar disorder: theories, mechanisms and key clinical trials. , 0, , 44-61.		0
136	From attitudes to behavioral intentions: Stigma and bipolar disorder. Journal of Nursing Education and Practice, 2014, 4, .	0.2	0
137	Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines. Canadian Journal of Psychiatry, 2017, 62, 77-78.	1.9	0
138	Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression. Canadian Journal of Psychiatry, 2017, 62, 353-354.	1.9	0
139	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. Focus (American Psychiatric Publishing), 2021, 19, 76-85.	0.8	0
140	Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial. CNS Spectrums, 2021, 26, 169-170.	1.2	0
141	Evidence of a Dose-Response Relationship Between Program Interactivity and Outcomes Among Students. Psychiatric Services, 2020, 71, 874-875.	2.0	0
142	Psychiatric Prescribing Patterns for Depression Treatment in an Outpatient Depression Clinic. Psychopharmacology Bulletin, 2020, 50, 28-34.	0.0	0
143	Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer. Psychopharmacology Bulletin, 2021, 51, 109-124.	0.0	0
144	Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2023, 8, 162-170.	1,5	0

#	Article	IF	CITATIONS
145	Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study. Psychopharmacology Bulletin, 2021, 51, 8-30.	0.0	0